The longer-lasting version was approved for the treatment of schizophrenia in adults. Currently, in addition to a pill format, Lilly also makes a fast-acting injection of the drug that can be absorbed by the body in a few hours to treat agitation. Patients taking regular Zyprexia take the pill daily while the new version will allow patients to visit their doctors every two or four weeks to receive an injection.
Lilly shares rose 32 cents to $35.29 in Monday morning trading.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine
